NCT02553603

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: The University of Texas Medical Branch, Galveston · Academic / Other
• Sex: All
• Age: 55 Years – 85 Years
• Healthy volunteers: Accepted

Summary

This study is examining the effects of growth hormone releasing hormone (GHRH) on mild cognitive impairment (MCI). GHRH will be given at a dose of 1mg/day for 10 weeks to subjects with MCI as well as healthy controls.

Detailed description

Subjects with MCI as well as healthy controls will be given GHRH at a dose of 1mg/day for 10 weeks. This study is designed to investigate the effects of GHRH on the following things: 1) cognitive function as measured by our neuropsychologist with a series of short tests; 2) brain activity as measured by fMRI 3) lean and fat mass of your body as measured by DEXA; 4) physical function as measured by a walking test.

Conditions

• Mild Cognitive Impairment

Interventions

Type	Name	Description
DRUG	Growth Hormone Releasing Hormone (GHRH)	Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
DRUG	Placebo Growth Hormone Releasing Hormone	Placebo GHRH to be given once daily for 10 weeks

Timeline

• Start date: 2017-07-18
• Primary completion: 2019-01-17
• Completion: 2019-01-17
• First posted: 2015-09-17
• Last updated: 2019-11-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study